Researchers propose compatibility-based framework for proteostasis networks and aggregate structures in neurodegeneration

A newly proposed framework reframes neurodegeneration as a dynamic compatibility mismatch between specific protein aggregate structures and localized cellular proteostasis networks, suggesting that therapeutic strategies must look beyond uniform proteostasis decline.

In a paper published in Philosophical Transactions of the Royal Society B, researchers proposed that the cellular vulnerability and clinical heterogeneity of neurodegenerative diseases are determined by the dynamic interaction between aggregate structures and cell-type-specific proteostasis networks.

The authors proposed that rather than representing a uniform collapse of cellular proteostasis, neurodegeneration is better understood as a compatibility failure between specific structural identities of protein aggregates and the changing cellular protein quality control networks that process them.

According to the publication, proteostasis networks vary between cell types, disease states, and during the aging process in their overall composition, capacity, and plasticity, meaning a single aggregate structure can propagate in one cellular environment but be cleared in another.

This framework provides a conceptual explanation for selective cellular vulnerability, clarifying why specific neuronal populations succumb to pathology while adjacent, seemingly similar cells remain unaffected.

By emphasizing localized network compatibility rather than global cellular collapse, the model highlights the potential limitations of broad-spectrum proteostasis-boosting therapies in clinical development.

For drug developers targeting age-related proteostasis decline, this model suggests a need to transition from evaluating therapies in simplified, uniform in vitro assays to more complex, cell-type-specific models that reflect localized network biology.

Therapeutics designed to clear or prevent specific protein aggregates, such as tau-targeting platforms, may need to incorporate dynamic patient stratification based on localized proteostasis capacity rather than assuming uniform aggregate clearance across all cellular environments.

The potential adoption of this framework in preclinical screening platforms, specifically the development of assays that evaluate proteostasis modifiers against precise aggregate strains in human iPSC-derived cellular systems.